Ondine Biomedical Inc - Asset Resilience Ratio

Latest as of September 2008: 39.85%

Ondine Biomedical Inc (OBI) has an Asset Resilience Ratio of 39.85% as of September 2008. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check OBI PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

GBX1.88 Million
≈ $228.22 USD Cash + Short-term Investments

Total Assets

GBX4.71 Million
≈ $572.65 USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2006–2007)

This chart shows how Ondine Biomedical Inc's Asset Resilience Ratio has changed over time. See OBI net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Ondine Biomedical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OBI market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents GBX0.00 0%
Short-term Investments GBX1.88 Million 39.85%
Total Liquid Assets GBX1.88 Million 39.85%

Asset Resilience Insights

  • Very High Liquidity: Ondine Biomedical Inc maintains exceptional liquid asset reserves at 39.85% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Ondine Biomedical Inc Industry Peers by Asset Resilience Ratio

Compare Ondine Biomedical Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 65.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hugel Inc
KQ:145020
Biotechnology 29.57%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Absci Corp
NASDAQ:ABSI
Biotechnology 59.86%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%

Annual Asset Resilience Ratio for Ondine Biomedical Inc (2006–2007)

The table below shows the annual Asset Resilience Ratio data for Ondine Biomedical Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2007-12-31 43.12% GBX5.61 Million
≈ $682.19
GBX13.00 Million
≈ $1.58K
-15.66pp
2006-12-31 58.78% GBX10.85 Million
≈ $1.32K
GBX18.46 Million
≈ $2.25K
--
pp = percentage points

About Ondine Biomedical Inc

LSE:OBI UK Biotechnology
Market Cap
$916.61K
GBX7.53 Billion GBX
Market Cap Rank
#30562 Global
#823 in UK
Share Price
GBX14.50
Change (1 day)
+0.00%
52-Week Range
GBX8.00 - GBX18.00
All Time High
GBX58.50
About

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more